GlassScriptPhysician profile
Edgar H Clark
NPI 1003847872
$2,611.38
in general payments reported to CMS, 2019-2025
32 companies · $211 in 2025
The $211 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $812 · 2022: $344 · 2023: $718 · 2024: $525 · 2025: $211.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,455.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $586.39 | 2021-2025 | Vraylar, Qulipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $271.36 | 2022-2025 | Jardiance |
| Otsuka America Pharmaceutical, INC. | $206.86 | 2023-2024 | Rexulti |
| Biohaven Pharmaceuticals, INC. | $203.56 | 2021 | |
| Novo Nordisk INC | $157.88 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $140.53 | 2021-2024 | Mounjaro, Jardiance |
| Merck Sharp & Dohme LLC | $117.76 | 2021-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Amgen INC. | $108.68 | 2021-2024 | Otezla, Repatha |
| Biohaven Pharmaceutical Holding Company LTD. | $92.45 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $75.85 | 2021-2023 | Farxiga |
| Daiichi Sankyo INC. | $55.10 | 2021-2024 | Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $52.23 | 2021 | |
| Dynavax Technologies Corporation | $51.32 | 2024 | Heplisav-B |
| Amarin Pharma, INC. | $39.00 | 2021 | |
| Mylan Specialty L.P. | $37.93 | 2023-2024 | Yupelri |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Phathom Pharmaceuticals, INC. | $36.10 | 2024-2025 | Voquezna |
| Optos, INC. | $36.04 | 2021-2022 | |
| Nalu Medical, INC. | $35.49 | 2025 | Nalu Neurostimulation System |
| Bayer Healthcare Pharmaceuticals INC. | $34.44 | 2022 | |
| Cranial Technologies, INC | $32.18 | 2021-2023 | Doc Band |
| Axsome Therapeutics, INC. | $29.42 | 2024 | Auvelity |
| Sumitomo Pharma America, INC. | $27.10 | 2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $23.06 | 2021 | |
| Ultragenyx Pharmaceutical INC. | $22.27 | 2023 | |
| Esperion Therapeutics, INC. | $20.98 | 2021 | |
| Verity Pharmaceuticals INC. | $20.23 | 2025 | Tlando |
| Glaxosmithkline, LLC. | $18.82 | 2021 | |
| Pfizer INC. | $18.80 | 2023 | |
| Sanofi Pasteur INC. | $16.76 | 2021 | |
| Janssen Pharmaceuticals, INC | $15.63 | 2023 | Spravato |
| Idorsia Pharmaceuticals US INC | $15.02 | 2024 | Quviviq |
| Eisai INC. | $12.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edgar Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.